Covalent Group, Inc. has signed a $2.3 million contract with a biotechnology company for the conduct of a multinational Phase II trial of a new anti-thrombotic agent. This trial will assess the efficacy and safety of the study drug in an at-risk patient population. Work on the study is expected to begin immediately. Covalent will provide multiple services including consulting on trial design and protocol development, project and study site management, field operations, data management, biostatis...